SMTL ID : 7oy6.1

Crystal structure of human DYRK1A in complex with ARN25068

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.38 Å

Oligo State

monomer

Ligands

1 x 39I: ~{N}4-(3-cyclopropyl-1~{H}-pyrazol-5-yl)-~{N}2-(phenylmethyl)thieno[3,2-d]pyrimidine-2,4-diamine(Non-covalent)

39I.1: 15 residues within 4Å: Chain A: G.40, K.41, F.44, V.47, A.60, F.112, E.113, L.115, S.116, Y.117, N.118, D.121, E.165, L.168, V.180 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:F.44, A:V.47, A:V.47, A:A.60, A:F.112, A:F.112, A:L.168, A:V.180 Hydrogen bonds: A:L.115, A:L.115, A:L.115

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Demuro, S. et al., ARN25068, a versatile starting point towards triple GSK-3 beta /FYN/DYRK1A inhibitors to tackle tau-related neurological disorders. Eur.J.Med.Chem. (2022)

Release Date

2022-03-02

Peptides

Dual specificity tyrosine-phosphorylation-regulated kinase 1A: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

Dual specificity tyrosine-phosphorylation-regulated kinase 1A